Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

FDA approves BMS's Yervoy in pediatric melanoma

Chris Lieu
September 8, 2017 4:15 PM UTC

FDA approved a label expansion for Yervoy ipilimumab (BMS-734016) from Bristol-Myers Squibb Co. (NYSE:BMY) to treat unresectable or metastatic melanoma in pediatric patients ages ≥12.

Yervoy is already approved to treat unresectable or metastatic melanoma in adults and as adjuvant therapy for cutaneous melanoma with pathologic involvement of regional lymph nodes of >1 mm in patients who have undergone complete resection, including total lymphadenectomy...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Bristol Myers Squibb Co.

Ono Pharmaceutical Co. Ltd.